A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Conditions

• Melanoma
• Breast Carcinoma
• Hepatocellular Carcinoma
• Urothelial Carcinoma
• Squamous Cell Carcinoma of the Head and Neck
• Renal Cell Carcinoma
• Colorectal Carcinoma
• Non-small Cell Lung Carcinoma
• Gastric or Gastroesophageal Junction Adenocarcinoma
• Endometrial Carcinoma
• Mesothelioma
• Neuroendocrine Carcinoma
• Cervical Cancer
• Small Cell Lung Carcinoma
• Squamous Cell Carcinoma of the Anus
• Castration-Resistant Prostate Carcinoma
• Nasopharyngeal Carcinoma
• Cholangiocarcinoma
• Basal Cell Carcinoma
• Ovarian Carcinoma
• Fallopian Tube Carcinoma
• Thymoma
• Thymic Carcinoma
• Squamous Cell Carcinoma of the Penis
• Vulvar Carcinoma
• Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy
• Malignant Adnexal Neoplasms
• Non-squamous Cell Salivary Gland Carcinoma

Interventions

• BIOLOGICAL: XmAb20717

Sponsor

Xencor, Inc.

Collaborators

• [object Object]